Back to Treatment

Treatment: Treatment

Medication and surgery for adults

Last updated 18-06-2020

Treatment guidelines recommend consideration of additional therapies such as pharmacotherapy and bariatric surgery when behavioural intervention has not achieved sufficient weight loss to improve health or quality of life. This page summarises the evidence for the use of medications, gastrointestinal devices and bariatric surgery to treat adults with overweight and obesity.

Key Evidence

01

Pharmacotherapy is indicated in addition to behavioural intervention in overweight people with a weight-related health problem, or people with obesity

02

Four medications are approved by the Therapeutic Goods Administration (TGA) for the treatment of obesity in Australia

03

Gastrointestinal devices are a relatively new weight loss therapy and an emerging field of research

04

Bariatric surgery is the most efficacious long-term treatment for severe obesity and should be considered with regard to individual circumstances

This page has been written by Dr Priya Sumithran, Associate Professor Tania Markovic and Associate Professor Samantha Hocking; and reviewed by Professor Ian Caterson.

Overweight and obesity have complex biological, psychosocial and environmental determinants, and are not simply the result of a poor lifestyle. Behavioural intervention, including changes in eating habits and physical activity, is the foundation of obesity management. The resulting weight loss, however, sets in motion a long-lasting, counter-regulatory biological response, including a reduction in total energy expenditure greater than expected for the amount of lean mass lost, an increase in appetite, and changes in several hormones which influence energy balance,12 which amounts to a physiological defence against weight loss. It is therefore not surprising that obesity, like other chronic conditions, is not ‘cured’ by the initial phase of treatment (in this case, weight loss), and requires long-term, multidisciplinary management.

Treatment guidelines recommend consideration of additional therapies such as pharmacotherapy and bariatric surgery when behavioural intervention alone has not achieved sufficient weight loss to improve health or quality of life.34

Medications

Pharmacotherapy is indicated in addition to behavioural intervention in overweight people (BMI ≥ 27 kg/m2) with a weight-related health problem, or people with obesity (BMI > 30 kg/m2). In conjunction with behavioural intervention, pharmacotherapy may be useful in inducing weight loss, or preventing weight regain. Four medications are approved by the Therapeutic Goods Administration (TGA) for the treatment of obesity in Australia (Table 1) – phentermine, orlistat, liraglutide and naltrexone-bupropion. With the exception of orlistat, which reduces absorption of ingested calories, the medications used to treat obesity primarily act via effects on appetite (reducing hunger and/or increasing satiation).

The choice of medication is dependent on individual factors and preferences. There are very few randomised studies of phentermine monotherapy, or comparisons of the available medications against each other, but clinical trials indicate that on average, the available agents have similar weight loss efficacy, of around 4–6% over 12 months (Table 1). There is considerable variation between individuals in treatment response: in an analysis of randomised clinical trials of people with and without T2D who used liraglutide, naltrexone-bupropion and orlistat at the recommended doses for ≥1 year, weight loss of 5% or more was achieved by (respectively) 63, 55 and 44% of participants (compared with 23% of placebo participants) and ≥10% weight loss occurred in 34, 30 and 20% of participants after 12 months’ use (compared with 9% of placebo).5 It should be noted that some of the studies included in this analysis used very intensive behavioural interventions, and weight outcomes in both placebo and active intervention groups are often better in clinical trials compared with real-world results.

Weight loss of 5% is sufficient to bring about an improvement in weight-related complications. See Health benefits of weight loss. All of the available medications are associated with improvements in cardiometabolic risk profile, although each medication has favourable effects on different risk factors, and none is consistently superior.6 Liraglutide and orlistat are associated with reductions in fasting glucose, HbA1c (a measure of average blood glucose), risk of developing type 2 diabetes, and blood pressure; orlistat has the greatest effect on reducing low-density lipoprotein (LDL) cholesterol, and naltrexone-bupropion is associated with a moderate increase in high-density lipoprotein (HDL) cholesterol.6

Data on long-term safety and effectiveness of obesity medication are limited, but since the compensatory biological response to weight loss is long-standing, it is expected that treatment is required over the long-term, as is the case for other chronic conditions. It is recommended that medications are discontinued if they are ineffective after 12 weeks of the maximum tolerated dose, or if there are significant or persistent adverse effects.7

Equitable access to obesity medications is lacking, as none are subsidised under the Pharmaceutical Benefits Scheme (PBS). There are no cost-effectiveness analyses for use of these medications in the Australian context.

Table 1: Medications approved for the treatment of obesity in Australia Phentermine (Duromine® Metermine®) Liraglutide (Saxenda®) Naltrexone-Bupropion (Contrave®) Orlistat (Xenical®)
Dosage form Capsule Injection Tablet Tablet
Average weight loss (above behavioural intervention alone) 6% at 20 weeks [8] 6% at 1 year [9] 5% at 1 year [10] 4% at 1 year [11]
Proportion of participants with 5% and 10% weight loss at 1 year Not reported 63 and 33% (vs 27 and 11% with behavioural intervention alone) 48 and 25% (vs 16 and 7% with behavioural intervention alone) 73 and 41% (vs 45 and 21% with behavioural intervention alone)
Common side effects Hypertension, palpitations, tachycardia, insomnia, dry mouth, restlessness Nausea, vomiting, diarrhoea, constipation, abdominal pain, increased heart rate Nausea, headache, tachycardia, hypertension, insomnia, dry mouth Steatorrhoea, oily spotting, fat-soluble vitamin deficiency
Other Recommended for short-term (maximum 12 week) use Risk of developing type 2 diabetes reduced by 79% in people with pre-diabetes at 1 year Risk of developing type 2 diabetes reduced by 45% in people with pre-diabetes at 4 years

Sources for table:

Phentermine8; Liraglutide9; Naltrexone-Bupropion10; Orlistat11

Over-the-counter weight loss supplements

There are a plethora of non-prescription weight loss supplements and herbal medicines available for sale in pharmacies and supermarkets in Australia and sales suggest that they are widely consumed. They promise easy weight loss but there is no evidence that any of these products are of any value to assist weight loss and some may be counterproductive or potentially unsafe.12

Gastrointestinal devices

Gastrointestinal devices are a relatively new weight loss therapy and an emerging field of research. They are usually inserted endoscopically and result in weight loss that is generally greater than that achieved with medication but less than with surgical procedures.

One of the first such procedures was the gastric balloon but this needs to be removed after 6 months (after which weight regain usually occurs) and there have been life threatening complications with some of the devices (e.g. perforation of the oesophagus or stomach, pancreatitis, death), which have been withdrawn.

The EndoBarrier™ is a thin plastic sleeve that lines the first 60 cm of the small intestine such that food can longer be absorbed here resulting in weight reduction. However, the device needs to be removed within 12 months of insertion.

Aspiration therapy involves the placement of a small tube with an access port in the stomach that allows the patient to remove 30% of ingested calories after each meal. This treatment is safe and surprisingly effective as it modifies eating behaviour.

One of the newer procedures is the endoscopic sleeve gastrectomy in which stitches are placed inside the stomach to reduce its capacity by 70%. Complications are infrequent but can be severe and include gastrointestinal bleeding and fluid leak or collection from the stomach. These procedures usually result in 15% weight loss.

Bariatric surgery

Bariatric surgery should be considered as part of a comprehensive multidisciplinary treatment program taking into account the individual situation. National guidelines recommend bariatric surgery for adults with:

  • BMI >40 kg/m2
  • BMI >35 kg/m2 with comorbidities expected to improve with weight loss, and
  • BMI >30 kg/m2 with type 2 diabetes and inadequate glycaemic control despite optimal medical treatment.313

The three most common bariatric procedures in Australia are the sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB) and laparoscopic adjustable gastric banding (LAGB). The choice of procedure depends on the individual goals of treatment, available expertise (surgeon and institution), patient preferences, and personalised risk stratification.14 There have been considerable improvements in the safety of bariatric surgery over recent decades, partly due to the increasing use of laparoscopic procedures, and perioperative mortality rates are now less than 0.3%.15

Bariatric surgery is the most efficacious long-term treatment for obesity. LAGB achieves a mean weight reduction of 15–20% at 1 year, and larger weight losses of around 25–30% are seen with SG and RYGB.16 17 As with all obesity treatments, there is considerable inter-individual variation in response: more than half of people who undergo RYGB will have weight loss of 25% or more at 1 year. Some weight regain (on average 5–10% at 10 years) is expected in the longer term.18

Bariatric surgery also results in marked improvements in most weight-related health conditions, particularly type 2 diabetes (T2D), after RYGB and SG, and to a lesser extent, LAGB. In a meta-analysis of randomised controlled trials comparing surgery with medical treatment of T2D in 463 patients with follow-up of at least 2 years, diabetes remission was seen in 53% of bariatric surgery participants compared with 4% of participants who did not undergo surgery.19 In four studies with 5 years’ follow-up, diabetes remission was seen in 28% of surgical and 4% of medically-treated participants.19 Available evidence from observational cohort studies indicates a lower risk of microvascular events (damage to eyes, kidneys and nerves) after bariatric surgery compared to non-surgical treatment in people with T2D after at least 5 years’ follow-up,20 and of cardiovascular events and overall mortality in people with and without diabetes.21 Surgical treatment of obesity is also associated with improvements in cardiometabolic risk factors and numerous other weight-related issues such as obstructive sleep apnoea,22 non-alcoholic fatty liver disease,23 cancer incidence,24 sexual function25 and quality of life, particularly physical wellbeing.26

As with medical treatment of obesity, there is inequitable access to bariatric surgery in Australia. The potential demand for bariatric surgery far outstrips supply – it was estimated that of the 3.35 million Australians with obesity aged 18 to 65 years in 2011–2013, more than one quarter were potentially eligible for bariatric surgery (accounting for 6% of the population aged 18–65 years), of whom nearly half (46%) did not have private health insurance and 35% resided outside a major city.27 In 2014–15, there were just over 22,700 weight loss surgery procedures performed in Australia, the vast majority of which (88%) occurred in private hospitals. A meta-analysis of 61 studies concluded that overall, bariatric surgery is cost saving over the life course, even without considering indirect costs such as reduction in medication usage.28

References

1. Sumithran P, Proietto J. The defence of body weight: A physiological basis for weight regain after weight loss. Clinical Science 2013;124:231–41
2. Fothergill E, et al, Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity 2016;24:1612–9.
3. Australian Diabetes Society, the Australian and New Zealand Obesity Society and the Obesity Surgery Society of Australian and New Zealand 2016. The Australian Obesity Management Algorithm.
4. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel. Executive summary: Guidelines (2013) for the management of overweight and obesity in adults. Obesity 2014;22:S5–S39
5. Khera R et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016;315:2424–34
6. Khera R et al. Effects of Weight Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-Analysis. Gastroenterology 2018;154:1309–19
7. Therapeutic Goods Administration, Australian Public Assessment Report for Liraglutide, 2019. Available at https://www.tga.gov.au/sites/default/files/auspar-liraglutide-190429.pdf
8. Weintraub M et al. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984;144:1143–8.
9. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015;373:11–22.
10. Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595–605.
11. Torgerson J et al. XENical in the prevention of diabetes in obese subjects (XENDOS)study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–61.
12. Maunder A, Bessell E, Lauche R, Adams J, Sainsbury A, Fuller NR. Effectiveness of herbal medicines for weight loss: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2020 Jan 27. doi: 10.1111/dom.13973
13. Rubino F et al. (2016). Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care; 39:861-77
14. Mechanick J et al. Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient—2013 Update: Cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity 2013;21:S1–S27
15. Chang S et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg. 2014 Mar;149(3):275–87.
16. Buchwald H et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.
17. Schauer P et al. Clinical Outcomes of Metabolic Surgery: Efficacy of Glycemic Control, Weight Loss, and Remission of Diabetes. Diabetes Care 2016;39:902–11
18. Sjostrom L et al. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. N Engl J Med 2004;351:2683–93
19. Khorgami Z et al. Outcomes of Bariatric Surgery Versus Medical Management for Type 2 Diabetes Mellitus: a Meta-Analysis of Randomized Controlled Trials. Obesity Surgery 2019;29:964–74
20. Sheng B et al. The Long-Term Effects of Bariatric Surgery on Type 2 Diabetes Remission, Microvascular and Macrovascular Complications, and Mortality: a Systematic Review and Meta-Analysis. Obes Surg 2017; 27:2724–32
21. Kwok CS et al. Bariatric surgery and its impact on cardiovascular disease and mortality: A systematic review and meta-analysis. Int J Cardiol 2014;173:20–8
22. Zhang Y et al. Improvement in Nocturnal Hypoxemia in Obese Patients with Obstructive Sleep Apnea after Bariatric Surgery: a Meta-Analysis. Obes Surg 2019;29:601–8
23. Lee Y et al. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. Clinical gastroenterology and hepatology 2019;17:1040–60
24. Wiggins T et al. (2019). Cancer Risk Following Bariatric Surgery—Systematic Review and Meta-analysis of National Population-Based Cohort Studies. Obesity Surgery; 29:1031–39
25. Xu J et al. Effect of Bariatric Surgery on Male Sexual Function: A Meta-Analysis and Systematic Review. Sexual Medicine 2019;7:270–81
26. Lindekilde N et al. The impact of bariatric surgery on quality of life: a systematic review and meta-analysis. Obes Rev 2015;16:639–51
27. Sharman M et al. Population estimates and characteristics of Australians potentially eligible for bariatric surgery: findings from the 2011–13 Australian Health Survey. Australian Health Review 2018;42:429–37
28. Xia Q et al. Bariatric surgery is a cost‐saving treatment for obesity—A comprehensive meta‐analysis and updated systematic review of health economic evaluations of bariatric surgery. Obesity Reviews. 2020;21:e12932